In our opinions, more details of immune checkpoint inhibitors treating NSCLC patients with different genes mutation, not only EGFR or KRAS, but also ALK, BRAF and the like, in RCTs need to be complementarily reported. This evidence concerns the gene KRAS and non-small cell lung carcinoma.